logo

For the Inventor, By the Inventor

Freiburg, Germany

Eugen Leo

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Isarna Therapeutics Gmbh. Active years: 2017-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eugen Leo. Retrieved from https://idiyas.com/inventor/eugen-leo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • Freiburg, DE (2017 - 2018)
  • Munich, DE (2021)

Company Filing History:

goldMedal3 out of 6 
 
Isarna Therapeutics Gmbh
 patents

Years Active: 2017-2021

Loading Chart...
3 patents (USPTO):Explore Patents
1. 11207341 - TGF-beta oligonucleotide for use in treatment of ophthalmic diseases (2021-12-28),
2. 10125368 - Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease (2018-11-13),
3. 9688988 - Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease (2017-06-27),

Title: Eugen Leo: Innovator in Ophthalmic Treatments

Introduction

Eugen Leo is a prominent inventor based in Freiburg, Germany. He has made significant contributions to the field of ophthalmology through his innovative patents. With a total of 3 patents, his work focuses on developing oligonucleotides for the treatment of various ophthalmic diseases.

Latest Patents

Eugen Leo's latest patents include a TGF-beta oligonucleotide designed for use in the treatment of ophthalmic diseases. This invention involves an oligonucleotide comprising a nucleic acid sequence of SEQ ID No. 1 or parts thereof, with modifications at the 3'-end and/or 5'-end to reduce or inhibit scarring and fibrotic closure of the trabeculectomy canal. Additionally, it aims to protect the optic nerve. Another significant patent is a modified TGF-beta oligonucleotide that consists of 10 to 20 nucleotides from selected regions of the TGF-beta1, TGF-beta2, or TGF-beta3 nucleic acid sequence. This invention is intended for the prevention and treatment of conditions such as glaucoma, dry eye, and age-related macular degeneration.

Career Highlights

Eugen Leo is currently associated with Isarna Therapeutics GmbH, where he continues to advance his research in ophthalmic treatments. His work has garnered attention for its potential to improve patient outcomes in various eye diseases.

Collaborations

Eugen collaborates with notable colleagues, including Michel Janicot and Frank Jaschinski, who contribute to his research endeavors.

Conclusion

Eugen Leo's innovative work in the field of ophthalmology highlights his commitment to advancing medical treatments. His patents reflect a deep understanding of the complexities of eye diseases and the potential for new therapeutic approaches.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…